In the past 12‑18 months the Pharmaceutical Grade Melatonin market has accelerated through a blend of strategic alliances and regulatory milestones. In Q2 2024, NeuroHealth Labs partnered with EuroPharma to co‑develop a GMP‑certified, extended‑release melatonin formulation targeting sleep‑disordered breathing, leveraging EuroPharma’s European distribution network. Meanwhile, Sunrise Biotech acquired CalmRx for $85 million, consolidating the latter’s patented transdermal melatonin patch technology and expanding the combined pipeline into pediatric insomnia. The first FDA‑approved, prescription‑strength, 5 mg sublingual melatonin tablet launched in August 2024, promising faster onset and reduced variability compared with over‑the‑counter products. On the regulatory front, the European Medicines Agency (EMA) updated its monograph in November 2023, tightening purity thresholds to 99.5 % and mandating third‑party batch testing, prompting manufacturers to upgrade quality‑control processes. Consumer demand has shifted toward clinically validated, “pharma‑grade” solutions, driving a 22 % YoY increase in B2B contracts with sleep‑clinic chains. Finally, Luna Therapeutics secured a $45 million Series B round to scale its GMP‑grade melatonin manufacturing facility in Singapore, positioning it as a regional supply hub. Collectively, these activities illustrate the evolving Pharmaceutical Grade Melatonin industry trends and set the stage for broader clinical adoption.
